Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Anterogen.Co.,Ltd., a South Korean bio-venture founded in 2000 and headquartered in Seoul, specializes in the global research, development, and commercialization of therapeutic products utilizing adipose-derived stem cells. Their pharmaceutical offerings include Cupistem injection, an adipose stem cell product for treating Crohn's fistula; Queencell, a stromal vascular fraction aimed at regenerating subcutaneous adipose tissue; and Remodulin injection, which addresses pulmonary arterial hypertension. The company also produces a line of cosmetics, featuring SCM2 and SCM2-Black for hair care, and Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione for skin care, along with providing human stem cell conditioned media as a cosmetic raw material. Furthermore, Anterogen offers services such as cell banking and various analytical services, including sample analysis for clinical studies and biopharmaceutical testing for identification, purity, potency, and adventitious viruses.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.